MK-5172 : a second-generation protease inhibitor for the treatment of hepatitis C virus infection. (Q34411907)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24666106%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

title

MK-5172 : a second-generation protease inhibitor for the treatment of hepatitis C virus infection (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24666106%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

1 reference

ChEBI release 2020-05-28

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24666106%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

Emanuela Zappulo

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24666106%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

Giuseppe Castaldo

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24666106%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

Guglielmo Borgia

6

1 reference

ORCID Public Data File 2021

author name string

Antonio Riccardo Buonomo

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24666106%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

Federico Borgia

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24666106%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

language of work or name

English

0 references

publication date

26 March 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24666106%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Investigational Drugs

12 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24666106%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

volume

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24666106%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24666106%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

page(s)

719-728

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24666106%20AND%20SRC:MED&resulttype=core&format=json

Evolving epidemiology of hepatitis C virus

12 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902049

Association of tattooing and hepatitis C virus infection: a multicenter case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902049

Improvement in the aetiological diagnosis of acute hepatitis C: a diagnostic protocol based on the anti-HCV-IgM titre and IgG Avidity Index

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902049

Age and gender distribution of hepatitis C virus genotypes in the metropolitan area of Naples

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902049

Hepatitis C: the clinical spectrum of disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902049

A Simple Noninvasive Score Based on Routine Parameters can Predict Liver Cirrhosis in Patients With Chronic Hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902049

Abdominal fat interacts with PNPLA3 I148M, but not with the APOC3 variant in the pathogenesis of liver steatosis in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902049

Multiple sclerosis and hepatitis C virus infection are associated with single nucleotide polymorphisms in interferon pathway genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902049

Increased hepatitis C viral load and reactivation of liver disease in HCV RNA-positive patients with onco-haematological disease undergoing chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902049

Erectile dysfunction in patients with chronic viral hepatitis: a systematic review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902049

Sustained virological response: a milestone in the treatment of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902049

Surrogate endpoints and non-inferiority trials in chronic viral hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902049

Effect of sustained virological response on long-term clinical outcome in 113 patients with compensated hepatitis C-related cirrhosis treated by interferon alpha and ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902049

Long-term clinical and virological outcomes of chronic hepatitis C after successful interferon therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902049

Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902049

Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902049

Efficacy of Pegylated interferon α-2a and α-2b in patients with genotype 1 chronic hepatitis C: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902049

Diagnosis, management, and treatment of hepatitis C: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902049

Vitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-alfa based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902049

Prediction of sustained virologic responses to combination therapy of pegylated interferon-α and ribavirin in patients with chronic hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902049

Homocysteine levels and sustained virological response to pegylated-interferon alpha2b plus ribavirin therapy for chronic hepatitis C: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902049

Raised serum ferritin predicts non-response to interferon and ribavirin treatment in patients with chronic hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902049

Iron depletion before HCV antiviral therapy: a pilot, randomized, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902049

Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naïve patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902049

Vitamin D improves viral response in hepatitis C genotype 2-3 naïve patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902049

Role of interleukin 28-B in the spontaneous and treatment-related clearance of HCV infection in patients with chronic HBV/HCV dual infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902049

Sustained virological response to antiviral treatment in chronic hepatitis C patients may be predictable by HCV-RNA clearance in peripheral blood mononuclear cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902049

Telaprevir: a promising protease inhibitor for the treatment of hepatitis C virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902049

Boceprevir for untreated chronic HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902049

The efficacy and safety of telaprevir - a new protease inhibitor against hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902049

A novel promising therapeutic option against hepatitis C virus: an oral nucleotide NS5B polymerase inhibitor sofosbuvir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902049

Antiviral strategies in hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902049

Perspectives and challenges of interferon-free therapy for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902049

Ledipasvir : a novel synthetic antiviral for the treatment of HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902049

Discovery of MK-5172, a Macrocyclic Hepatitis C Virus NS3/4a Protease Inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902049

Development of a practical, asymmetric synthesis of the hepatitis C virus protease inhibitor MK-5172.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902049

MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902049

Novel Quinoline-Based P2-P4 Macrocyclic Derivatives As Pan-Genotypic HCV NS3/4a Protease Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902049

Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902049

Virologic response and characterisation of HCV genotype 2-6 in patients receiving TMC435 monotherapy (study TMC435-C202).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902049

Bevacizumab: finding its niche in the treatment of heart failure secondary to liver vascular malformations in hereditary hemorrhagic telangiectasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902049

Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902049

Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902049

SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902049

Single- and multiple-ascending-dose studies of the NS3 protease inhibitor asunaprevir in subjects with or without chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902049

Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902049

Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902049

New therapeutic strategies in HCV: second-generation protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902049

10.1517/13543784.2014.902049

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24666106%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

1 reference